|
Dr.
Maroun and Dr. Fields discuss
the J.Y Douillard presentation
on Colorectal Cancer entitled:
Evolving
Strategies for Metastatic
Colorectal Cancer,
Superiority of Infusional
5FU-Based Combination Therapy
Intended
Audiences:
Oncology
clinicians
Objective:
Dr. Jean
Maroun, Chair of the Editorial
Committee of the Canadian
Oncology website site and
Medical Oncologist with
the Ottawa Regional Cancer
Centre and Medical Oncologist,
Dr. Anthony Fields, President
of the National Cancer Institute
of Canada (NCIC) & Vice
President, Medical Affairs
and Community Oncology,
Alberta Cancer Board discuss
and critique the presentation
by Professeur J.Y. Douillard
MD, PhD on colorectal cancer,
Evolving Strategies for
Metastatic Colorectal Cancer,
Superiority of Infusional
5-FU Based Combination Therapy,
recorded in September 2002
and available on the Pfizer-Pharmacia
oncology site: www.pharmacia.ca.
To view the password-protected
Douillard programme, please
contact a representative
of Pfizer Pharmacia write
to info@cos.ca.
Specific
goals:
In his presentation
in September 2002, “Evolving
Strategies for Metastatic
Colorectal Cancer, Superiority
of Infusional 5-FU Based
Combination Therapy”
Dr. Douillard examined the
Controversy surrounding
the Saltz vs. Folfox regimes.
Dr. Douillard also covered
the Intergroup study: Folfiri
(CPT 11 + LV 5FU); Folfox
(Oxaliplatin) vs. Folfox
(Oxaliplatin LV 5FU); Folfiri
(CPT 11).
Dr.
Maroun and Dr. Fields comment
on the relevance of sequential
therapy as presented by
Douillard; Xeloda as a replacement
for 5FU LV in combination
therapy; the Falcone study
and what can be anticipated
in terms of the use of three-drugs
(CPT-11, Oxaliplatin, 5FU-LV
or CPT-11, Oxaliplatin,
Xeloda) in adjuvant or neo-adjuvant
therapy. |
